-
Precision Biosciences Doses First Patient in FUNCTION-DMD Trial of PBGENE-DMD
Precision BioSciences, Inc. today announced the dosing of the first patient in the Phase 1/2 FUNCTION-DMD clinical trial, evaluating the safety, tolerability, and efficacy of PBGENE-DMD for the treatment of Duchenne. PBGENE-DMD is Precision’s investigational in vivo gene editing program designed to improve function by restoring near full-length dystrophin. PBGENE-DMD uses a single adeno-associated virus…
-
Precision BioSciences has dosed the first individual with their novel gene editing approach for individuals with Duchenne mutations between exons 45 and 55
Precision BioSciences has shared that the first participant in the FUNCTION_DMD clinical trial has received their investigational gene editing treatment, PBGENE-DMD. PBGENE-DMD delivers ARCUS nucleases via AAV9 to cut out exons 45-55 of the dystrophin gene, a therapeutic approach amenable to individuals with Duchenne with mutations in that region. Link to press release: https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-commences-dosing-phase-12-function-dmd Dear Duchenne…








